Oil Price Surge Adds Cost Pressure to Pharmaceutical Ingredient Logistics
The latest oil-price volatility is creating another layer of cost pressure for pharmaceutical manufacturers already managing fragile global supply chains. While active pharmaceutical ingredients and excipients are generally high-value products, their logistics remain exposed to fuel surcharges, longer routes, higher air-freight costs, insurance premiums and rising transportation expenses. The result is a growing gap between the quoted price of an ingredient and its true landed cost.
For pharmaceutical manufacturers, the cost of an ingredient does not end when a supplier issues a quotation.
There is also:
Freight + Fuel Surcharges + Insurance + Handling + Storage + Customs + Inventory Cost
That makes pharmaceutical logistics particularly sensitive to disruptions in global transportation.
The current oil-market environment is reinforcing that problem.
On September 2, Brent crude briefly reached about $97 per barrel before retreating to around $94, while WTI briefly exceeded $92. Market volatility remains closely linked to risks around Middle Eastern supply and the Strait of Hormuz.
For pharmaceutical ingredient buyers, the concern is not simply the price of crude.
It is how quickly an energy shock moves through the logistics chain.
Why Oil Prices Matter to Pharmaceutical Ingredients
Pharmaceutical supply chains depend on multiple transportation modes.
Ingredients can move by:
Ocean freight
Air freight
Road transportation
Rail
Multimodal combinations
Every mode has some exposure to energy prices.
Ocean carriers consume large quantities of marine fuel.
Trucks depend heavily on diesel.
Air cargo is particularly sensitive to jet-fuel prices.
Warehouses and distribution centers also face higher energy expenses.
As a result, an oil shock can affect pharmaceutical logistics before it has any visible effect on the underlying API price.
The Freight Bill Can Change Even When the API Price Does Not
Consider a hypothetical API purchase:
API value: $100,000
The supplier's product price may remain unchanged.
But if transportation costs increase:
Original freight: $4,000
New freight: $5,500
The buyer's effective procurement cost has increased by $1,500 even though the supplier has not changed the API price.
This is why pharmaceutical procurement teams increasingly need to evaluate landed cost rather than purchase price.
Fuel Surcharges Are Becoming More Important
Carriers commonly use fuel-surcharge mechanisms to pass part of their fuel-cost exposure to customers.
During the current energy shock, transportation companies have increased or introduced additional fuel-related charges.
Reuters reported in August that transportation companies including UPS, FedEx and Union Pacific were experiencing increased fuel-surcharge revenue, while shipping costs were also being affected by higher energy prices.
For pharmaceutical shippers, this creates an additional budgeting problem.
A freight quote obtained several weeks ago may no longer represent the actual transportation cost when the shipment moves.
Ocean Freight Faces a Double Effect
Pharmaceutical ingredients transported by sea can experience two simultaneous pressures.
Higher fuel costs
Carriers face higher bunker-fuel expenses.
Route disruption
Geopolitical instability can force vessels to take longer or more expensive routes.
The combination is more damaging than either factor alone.
A longer route means:
More nautical miles → More fuel consumption → Higher operating cost
At the same time, limited vessel availability can increase freight rates.
The Strait of Hormuz Adds Another Layer of Risk
The Strait of Hormuz is particularly important to global energy markets.
Disruptions around the waterway can affect crude and refined-product flows, which then influence fuel prices and transportation costs globally.
The current disruption has already altered global shipping patterns and created significant uncertainty around energy supply.
Recent market analysis has indicated that roughly one-fifth of global oil supply normally moves through the Strait of Hormuz, making disruption there particularly significant for energy and transportation markets.
For pharmaceutical companies, the impact can arrive indirectly.
Hormuz disruption
↓
Higher oil prices
↓
Higher marine and aviation fuel costs
↓
Higher freight surcharges
↓
Higher landed API cost
Air Freight Is More Vulnerable
Pharmaceutical companies often use air freight when an ingredient is urgently required.
This makes sense because APIs and specialized intermediates can be extremely valuable relative to their physical weight.
But the same characteristic that makes air freight attractive also makes it expensive.
When fuel prices rise, aviation logistics can react quickly.
In March, Reuters reported that air-freight rates had risen by as much as 70% on some routes amid Middle East-related disruptions.
For a pharmaceutical manufacturer facing a production deadline, there may be little choice.
The company can either:
Pay the higher air-freight cost
or
Risk a manufacturing delay.
That makes fuel volatility a potential production-risk issue rather than simply a logistics expense.
High-Value APIs Are Better Positioned to Absorb Freight Increases
Not all pharmaceutical ingredients face the same exposure.
Consider two products.
Product A
API value: $500,000 per metric ton
Product B
Excipient value: $2,000 per metric ton
A $1,000 increase in freight has a relatively small effect on Product A's value.
For Product B, the same increase can materially change the economics.
This means high-value APIs may remain relatively resilient to transportation shocks, while lower-value bulk pharmaceutical materials can become much more freight-sensitive.
Excipients Can Face Greater Landed-Cost Pressure
Many pharmaceutical excipients are significantly lower-value products than specialized APIs.
Examples include:
Starches
Cellulose derivatives
Lactose
Certain inorganic excipients
Bulk solvents
Basic processing materials
For these products, transportation can represent a meaningful portion of the final delivered cost.
When fuel prices rise, buyers may therefore reconsider sourcing distances.
A supplier that appears cheaper at the factory gate may become more expensive after freight.
Pharmaceutical Intermediates Sit Between the Two
Pharmaceutical intermediates can have very different economics depending on their chemistry and production scale.
Specialty intermediates may have sufficiently high value to tolerate expensive transportation.
Commodity intermediates may not.
Procurement teams should therefore classify materials according to value-to-weight ratio.
A useful framework is:
High value / low weight → Less freight-sensitive
Low value / high weight → More freight-sensitive
This can help determine where regional sourcing is most valuable.
Longer Routes Can Create Inventory Costs
Higher freight is only one part of the problem.
Longer transportation routes also increase transit time.
For pharmaceutical manufacturers, additional transit time can require more safety stock.
The chain becomes:
Longer route
↓
Longer lead time
↓
Higher safety stock
↓
More working capital
↓
Higher inventory carrying cost
The true cost of an energy shock can therefore exceed the freight surcharge shown on the carrier invoice.
Air Freight Can Become the Emergency Valve
When ocean transportation becomes slow or unreliable, pharmaceutical manufacturers may shift urgent shipments to air.
This creates a substitution effect.
Ocean disruption → Air-freight demand increases
But if the same geopolitical event is simultaneously disrupting aviation routes and raising jet-fuel costs, air freight becomes more expensive precisely when companies need it most.
This is one reason pharmaceutical supply chains can become vulnerable during prolonged disruptions.
Recent Events Show the Risk
The current geopolitical environment provides a useful example.
STAT reported in March that pharmaceutical supply chains had not experienced major global disruption at that point, although prolonged conflict could change the situation.
That distinction is important.
A supply chain does not have to experience an immediate shortage for manufacturers to feel the impact.
There can be a cost shock before a supply shock.
Pharmaceutical companies may still receive their APIs.
They simply pay more to move them.
Fuel Prices Can Change Supplier Economics
Imagine two API suppliers:
Supplier A — India
API price: $100/kg
Freight: $8/kg
Landed cost: $108/kg
Supplier B — Europe
API price: $104/kg
Freight: $3/kg
Landed cost: $107/kg
Supplier B is actually cheaper despite the higher factory-gate price.
Now increase transportation costs.
Supplier A's freight rises to $13/kg.
Supplier B's freight rises to $4/kg.
The new landed costs become:
Supplier A: $113/kg
Supplier B: $108/kg
The competitive ranking changes.
This is why procurement teams should avoid selecting suppliers based exclusively on quoted unit prices.
Regional Sourcing Becomes More Attractive
Persistent energy volatility could strengthen the case for regional pharmaceutical sourcing.
Instead of relying entirely on distant production centers, manufacturers may consider:
Regional API suppliers
Near-market warehouses
Dual manufacturing locations
Local packaging
Regional distribution hubs
This does not mean abandoning global sourcing.
It means balancing:
Unit cost
against
Logistics exposure
against
Supply continuity
India Remains Important to Global Pharma Supply
India is one of the world's major pharmaceutical manufacturing and API-production hubs.
Indian pharmaceutical suppliers serve markets across North America, Europe, Asia, Africa and other regions.
But long-distance exports can become more expensive when maritime and aviation fuel costs rise.
For buyers, this creates an important calculation:
Low production cost + high logistics exposure
versus
Higher production cost + lower logistics exposure
The cheapest manufacturing location is not always the cheapest supply-chain location.
China Faces a Similar Calculation
China remains a major supplier of pharmaceutical ingredients and chemical intermediates.
Its scale and manufacturing ecosystem can provide substantial cost advantages.
But shipments to distant pharmaceutical markets remain exposed to international freight rates.
As oil volatility increases, buyers may begin comparing Chinese suppliers with alternative regional sources using landed cost rather than factory price.
Energy Prices Can Also Affect Chemical Inputs
The relationship between oil and pharmaceutical ingredients is not limited to transportation.
Petrochemical-derived materials are used throughout the chemical and pharmaceutical supply chain.
Oil and natural-gas markets influence the economics of many chemical intermediates, solvents, polymers and packaging materials.
Therefore:
Oil shock → Transportation cost
and potentially:
Oil shock → Chemical input cost
The pharmaceutical industry can consequently experience two different channels of inflation.
Packaging Is Part of the Same Equation
Pharmaceutical products require specialized packaging.
This can include:
Plastic containers
Blister materials
Films
Coatings
Specialty polymers
Labels
Secondary packaging
Many packaging materials have energy-intensive production chains.
Higher energy costs can therefore affect both the ingredient and the packaging surrounding the final medicine.
Cold-Chain Logistics Are Even More Sensitive
Certain pharmaceutical products and biological materials require temperature-controlled transportation.
These supply chains consume additional energy through:
Refrigerated warehouses
Temperature-controlled vehicles
Active containers
Cold rooms
Monitoring systems
An energy shock can therefore create additional operational costs for temperature-sensitive pharmaceutical products.
For conventional APIs, the exposure may primarily be freight-related.
For temperature-sensitive materials, it can extend throughout the logistics chain.
Insurance Costs Can Rise Alongside Fuel Costs
Geopolitical disruptions can also increase insurance premiums.
When shipping routes become more dangerous, carriers and cargo owners may face higher war-risk or related insurance costs.
The result is another component of landed cost:
Product + Freight + Fuel surcharge + Insurance + Risk premium
This is particularly important for pharmaceutical products because cargo values can be high.
Procurement Contracts Need More Flexibility
Traditional long-term freight contracts provide price stability.
But extreme fuel volatility can encourage carriers to introduce adjustment mechanisms.
Pharmaceutical companies should therefore review:
Fuel-surcharge formulas
Adjustment frequency
Benchmark fuel prices
Surcharge caps
Contract escalation clauses
Emergency routing provisions
A contract that appears fixed-price may not actually be fixed-cost.
Buyers Should Track Fuel Benchmarks
Procurement teams should monitor fuel indicators alongside API pricing.
Useful indicators include:
Brent crude
WTI crude
Marine bunker fuel
Jet fuel
Regional diesel prices
These indicators can provide early warning of future transportation-cost increases.
Freight Quotes Need Expiration Dates
In volatile markets, freight quotations should not be treated as permanent.
A buyer requesting a quote today may receive a substantially different price when the shipment actually moves.
Procurement teams should therefore establish:
Quote validity periods
Fuel-surcharge assumptions
Expected shipping dates
Alternative routing options
Emergency freight provisions
This improves cost forecasting.
Route Optimization Can Offset Some Costs
Companies cannot control global oil prices.
They can control how their products move.
Potential strategies include:
Consolidating shipments
Increasing container utilization
Selecting efficient ports
Reducing unnecessary transshipments
Using regional distribution centers
Comparing ocean and air alternatives
Optimizing shipment frequency
Small improvements in logistics efficiency can become more valuable when fuel costs rise.
Consolidation Becomes More Valuable
Shipping small quantities repeatedly can create inefficient freight economics.
Where product stability and inventory requirements allow, manufacturers can consolidate orders.
Instead of:
10 small shipments
a company might move:
4 larger shipments
This can reduce the freight cost per kilogram.
However, pharmaceutical manufacturers must balance consolidation against inventory carrying costs and expiration risks.
Safety Stock Needs a More Sophisticated Formula
Increasing safety stock can protect against delays.
But excessive inventory ties up capital.
The better approach is to calculate safety stock according to:
Demand variability + Lead-time variability + Supplier reliability + Route risk
Fuel volatility should increasingly be included in the broader logistics-risk assessment.
Dual Sourcing Becomes More Valuable
A pharmaceutical manufacturer sourcing an API from a single distant location has limited flexibility when freight costs or routes change.
Dual sourcing can provide alternatives.
For example:
Primary supplier → Asia
Secondary supplier → Europe
If one route becomes uneconomical, procurement can shift part of the volume.
The second supplier does not need to be the cheapest.
It needs to provide strategic optionality.
But Switching Suppliers Is Not Instant
Pharmaceutical ingredients cannot always be switched like ordinary commodities.
Changing an API supplier can require:
Qualification
Quality audits
Analytical testing
Stability studies
Regulatory submissions
Process validation
This means supply-chain diversification needs to be planned well before a disruption occurs.
Digital Procurement Can Help
Fuel volatility strengthens the case for digital procurement platforms that combine:
Supplier price
Freight
Transit time
Insurance
Risk
Landed cost
A procurement dashboard can compare suppliers based on total delivered economics rather than simply displaying the lowest quotation.
For pharmaceutical manufacturers, this can significantly improve purchasing decisions during volatile markets.
The New Question: What Is the Delivered Cost?
The traditional procurement question is:
"Who sells the API cheapest?"
The more useful question is:
"Who can deliver the API at the lowest reliable landed cost?"
That distinction becomes increasingly important during energy shocks.
A supplier offering a $95/kg API may be less competitive than one offering $100/kg if the first supplier requires significantly higher freight, insurance and inventory costs.
What Pharmaceutical Buyers Should Do Now
Procurement teams can take several practical steps.
1. Recalculate landed costs
Update freight assumptions for major API and excipient categories.
2. Review fuel-surcharge clauses
Understand exactly how carriers pass energy costs to customers.
3. Segment products by freight sensitivity
Prioritize low-value, high-weight ingredients for logistics optimization.
4. Compare transport modes
Determine where ocean, rail, road and air alternatives make economic sense.
5. Review alternative suppliers
Identify qualified secondary sources before an emergency occurs.
6. Increase logistics visibility
Track route disruptions and freight-market changes alongside supplier pricing.
7. Model multiple oil scenarios
Use different fuel-price assumptions when preparing procurement budgets.
Three Scenarios Procurement Teams Should Model
Scenario 1 — Oil Stabilizes
Fuel prices decline or remain contained.
Freight surcharges moderate.
Companies can maintain existing sourcing strategies.
Scenario 2 — Oil Remains Elevated
Brent remains above historical planning assumptions.
Fuel surcharges remain elevated.
Manufacturers face sustained logistics inflation.
Scenario 3 — Major Supply Disruption
A prolonged geopolitical disruption pushes oil significantly higher while restricting major shipping routes.
Freight costs rise sharply.
Air cargo becomes expensive.
Transit times increase.
Alternative sourcing becomes strategically important.
The third scenario is the one procurement teams should stress-test even if it is not their base case.
The Biggest Risk Is Volatility
The pharmaceutical industry can absorb moderate increases in transportation costs.
The bigger challenge is unpredictability.
If freight costs rise gradually, companies can adjust contracts and budgets.
If costs jump suddenly, procurement teams may be forced into expensive emergency decisions.
Therefore, forecastability itself has economic value.
Conclusion
The latest oil-price surge is creating another cost challenge for pharmaceutical manufacturers already navigating geopolitical disruption, freight volatility and complex international supply chains.
Brent crude briefly approached $97 per barrel on September 2, reflecting continuing concern over Middle Eastern supply risks.
The immediate pharmaceutical impact may not necessarily appear as an API shortage.
It can appear first as:
Higher fuel surcharges
Higher ocean freight
More expensive air cargo
Longer routes
Higher insurance
Greater inventory requirements
Together, these factors can significantly increase the landed cost of pharmaceutical ingredients.
The effect will not be uniform.
High-value APIs can often absorb higher transportation costs more easily than low-value, bulk ingredients and excipients. Products requiring urgent air shipment or temperature-controlled logistics can be particularly exposed.
That makes value-to-weight ratio, route dependence and supplier geography increasingly important procurement variables.
For pharmaceutical manufacturers, the strategic response is not simply to wait for oil prices to fall.
It is to build a procurement model that can function when they do not.
That means combining supplier diversification with freight benchmarking, fuel-surcharge monitoring, route optimization and landed-cost analysis.
The key metric is no longer just:
API price per kilogram.
It is:
Total delivered cost per kilogram — with supply risk included.
As energy and geopolitical volatility become more persistent features of global trade, pharmaceutical procurement teams that can see freight costs before they become production costs will have a significant advantage.
Alkyd Resin - Long Oil CAS: 68333-62-0
